Last reviewed 2026-05-16 · How we verify

John L. Villano, MD, PhD — Portfolio Competitive Intelligence Brief

John L. Villano, MD, PhD pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

Therapeutic area mix

• Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
2. Brenda Cooper, MD · 1 shared drug class
3. Bristol-Myers Squibb · 1 shared drug class
4. EMS · 1 shared drug class
5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 shared drug class
6. Glycotope GmbH · 1 shared drug class
7. Grace Therapeutics Inc. · 1 shared drug class
8. Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for John L. Villano, MD, PhD:

• John L. Villano, MD, PhD pipeline updates — RSS
• John L. Villano, MD, PhD pipeline updates — Atom
• John L. Villano, MD, PhD pipeline updates — JSON

Cite this brief

Drug Landscape (2026). John L. Villano, MD, PhD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/john-l-villano-md-phd. Accessed 2026-05-16.

Related

• John L. Villano, MD, PhD full company profile
• All CI briefs
• Build a custom feed